BCL-2 in prostate cancer: A minireview
Authors:
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Apoptosis
- Vol. 8 (1) , 29-37
Abstract
Prostate cancer progression and the development of androgen-independent prostate cancer have been largely related to a number of genetic abnormality that affect not only the androgen receptor but...Keywords
This publication has 70 references indexed in Scilit:
- Novel strategies and therapeutics for the treatment of prostate carcinomaCancer, 2000
- Antisense oligonucleotides as therapeutic agentsJournal of Cellular Physiology, 1999
- Neuroendocrine differentiation in prostatic carcinomaThe Prostate, 1999
- Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferationThe Prostate, 1998
- Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancerThe Prostate, 1997
- Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal-stripped mediaThe Prostate, 1997
- TNF-mediated cytotoxicity and resistance in human prostate cancer cell linesThe Prostate, 1996
- Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancerThe Prostate, 1996
- Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implicationsCancer, 1992
- Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castrationThe Prostate, 1989